{"id":466663,"date":"2026-05-29T20:04:09","date_gmt":"2026-05-29T20:04:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/466663\/"},"modified":"2026-05-29T20:04:09","modified_gmt":"2026-05-29T20:04:09","slug":"lymph-node-surgery-and-cdk4-6-inhibitor-treatment-in-early-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/466663\/","title":{"rendered":"Lymph Node Surgery and CDK4\/6 Inhibitor Treatment in Early Breast Cancer"},"content":{"rendered":"


\n \t\t By Matthew Stenger<\/a>

\n\t\t

\n\t\t
\n\t\t Posted: 5\/29\/2026 1:02:00 PM
\n\t\t

\n Last Updated: 5\/29\/2026 1:49:41 PM
\n\t\t \n\t\t<\/p>\n

<\/p>\n

As reported in The Lancet Oncology<\/a> by Pfob et al, a pooled analysis of randomized trials showed that performance of lymph node surgery for the sole purpose of determining eligibility for CDK4\/6 inhibitor treatment does not appear to be a promising strategy in patients with early breast cancer.<\/p>\n

As stated by the investigators, \u201cOmitting sentinel lymph node biopsy (SLNB) and completion axillary lymph node dissection (cALND) in early-stage breast cancer reduces morbidity without compromising overall survival or recurrence rates. However, reduced axillary surgery restricts staging information, impacting eligibility for CDK4\/6 inhibitors. We evaluated the impact of omitting SLNB or cALND on CDK4\/6 inhibitor eligibility and the associated benefits and harms.\u201d<\/p>\n

Study Details <\/p>\n

The study used data from five randomized trials (SOUND, INSEMA, SENOMAC, monarchE, and NATALEE) that evaluated the safety of de-escalated lymph node surgery and adjuvant CDK4\/6 inhibitors in patients with early breast cancer. The primary outcome measure of the current analysis was the number needed to diagnose and treat with CDK4\/6 inhibitor\u2014ie, number of axillary surgeries leading to adjuvant CDK4\/6 inhibitor use to prevent one invasive disease-free survival event, distant disease-free survival event, or overall survival event at 5 years.<\/p>\n

Key Findings <\/p>\n

The study included 19,541 patients from the five trials. Median follow-up was 57.2 months (interquartile range = 44.1\u201381.6 months).<\/p>\n

For SLNB and ribociclib, the number needed to diagnose and treat for one prevented event at 5 years was 123 for invasive disease-free survival, 129 for distant disease-free survival, and 345 for overall survival.<\/p>\n

For cALND and abemaciclib, the number needed to diagnose and treat for one prevented event at 5 years was 106 for invasive disease-free survival, 119 for distant disease-free survival, and 807 for overall survival.<\/p>\n

The investigators concluded: \u201cPerforming SLNB or cALND solely to determine eligibility for CDK4\/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit.\u201d<\/p>\n

J\u00f6rg Heil, MD, of Breast Center Heidelberg, Hospital St Elisabeth & Heidelberg University Hospital, Heidelberg, Germany, is the corresponding author for The Lancet Oncology article.<\/p>\n

DISCLOSURE: The investigators reported that there was no external funding for the study. For full disclosures of the study authors, visit thelancet.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":" By Matthew Stenger Posted: 5\/29\/2026 1:02:00 PM Last Updated: 5\/29\/2026 1:49:41 PM …\n","protected":false},"author":2,"featured_media":265817,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,85,46],"class_list":["post-466663","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/466663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=466663"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/466663\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/265817"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=466663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=466663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=466663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}